Vectron Systems AG

  • ISIN: DE000A0KEXC7
  • Land: Deutschland

Nachricht vom 21.04.2017 | 10:41

Vectron Systems AG: Strong growth continues in first quarter 2017

Vectron Systems AG / Key word(s): Quarter Results

21-Apr-2017 / 10:41 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

In the first quarter 2017 the positive trend continued unabatedly. The sales according to BilRUG (German law on implementation of the directive 2013/34/EU) increased in the first three months by 40 % compared to the previous year from EUR 7.57m to EUR 10.62m. Vectron Systems AG still profited from the special economic activity caused by the new ECR guideline, which rules that all the POS systems in Germany have to be equipped with a tamper protection by 1 January 2020.  
The gross margin increased by 2.7 percentage points to 57.5 %. The EBITDA increased by 155 % to EUR 1.97m (previous year EUR 0.77m); the EBIT increased by 190 % from EUR 0.64m to EUR 1.84m and the EBT could even be increased by 231 % to EUR 1.83m (previous year EUR 0.55m).  Net profits grew by 189 % from EUR 0.42m to EUR 1.20m. Cash holdings increased by 44 % to EUR 12.28m. The company assumes that the positive trend will continue in the next months as the ECR guideline is expected to boost domestic sales even further. The second brand Duratec also shows a positive development. The sales of EUR 0.57m more than tripled compared to the previous year (EUR 0.17m).

Thomas Stümmler
Vectron Systems AG
Willy-Brandt-Weg 41
48155 Münster, Germany
phone +49 (0)251 2856 - 0
fax +49 (0)251 2856 - 564

21-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

23. MKK – Münchner Kapitalmarkt Konferenz

Für: Institutionelle Investoren & Presse

Wann: 26. & 27. April 2017, 9 - 17 Uhr

Wo: The Charles Hotel - Rocco Forte Hotels, München

GBC im Fokus

Neovacs S.A.: Kursziel auf 3,30 € angehoben

In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.

Aktueller Webcast

Scout24 AG

Q1 Results 2017

10. Mai 2017

Aktuelle Research-Studie

JDC Group AG

Original-Research: JDC Group AG (von GBC AG): Kaufen

24. April 2017